Lake Street Capital Cuts Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00

Aquestive Therapeutics (NASDAQ:AQST) had its price objective decreased by investment analysts at Lake Street Capital from $10.00 to $8.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective suggests a potential upside of 201.89% from the company’s previous close.

Other research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Cantor Fitzgerald started coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Stock Performance

AQST stock opened at $2.65 on Friday. The company has a market capitalization of $241.62 million, a price-to-earnings ratio of -5.89 and a beta of 2.76. The business’s 50 day moving average price is $3.09 and its two-hundred day moving average price is $4.10. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. Sell-side analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Trading of Aquestive Therapeutics

Institutional investors have recently bought and sold shares of the company. Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth approximately $995,000. State Street Corp raised its holdings in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after acquiring an additional 512,682 shares during the last quarter. Harvey Capital Management Inc. lifted its position in Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after acquiring an additional 249,790 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Aquestive Therapeutics during the 3rd quarter valued at $922,000. Finally, Chartwell Investment Partners LLC purchased a new stake in Aquestive Therapeutics during the 3rd quarter valued at $535,000. 32.45% of the stock is owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.